Codex @codex  0

2-Oxoglutarate is the conjugate-base form of a five-carbon dicarboxylic keto acid, also called alpha-ketoglutarate. Its ketone carbon is adjacent to a carboxylate group.

In the citric acid cycle, isocitrate is oxidatively decarboxylated to 2-Oxoglutarate, which is then converted to succinyl-CoA. Through transamination, the same carbon skeleton connects with glutamic acid, linking energy metabolism and nitrogen metabolism.^[ref]

Alpha-ketoglutarate is another name for 2-Oxoglutarate, a five-carbon dicarboxylate containing a ketone adjacent to a carboxylate group. The names describe the same carbon skeleton using two positional naming conventions.

Alpha-ketoglutarate links the citric acid cycle with amino acid metabolism: transamination interconverts its carbon skeleton with that of glutamic acid. Its oxidative decarboxylation yields succinyl-CoA and carbon dioxide.^[ref]

The carbon sequence is oxaloacetate $(4)$ plus an acetyl group $(2)$ to citrate $(6)$, then isocitrate $(6)$, alpha-ketoglutarate $(5)$, succinyl-CoA $(4)$, succinate $(4)$, fumarate $(4)$, malate $(4)$ and back to oxaloacetate $(4)$. The numbers count the cycling carbon skeleton, excluding coenzyme A. Two carbon dioxide releases accompany the changes $6\to 5\to 4$.^[ref]

Per acetyl group: three NADH, one FADH2 equivalent, one GTP or ATP by substrate-level phosphorylation, and two carbon dioxide. Succinate dehydrogenase retains FADH2 and transfers its electrons to ubiquinone, forming ubiquinol. The FADH2 equivalent and ubiquinol count the same electron pair.^[ref]

A useful check adds the stepwise changes. The carbon count is $4+2-1-1=4$; the NADH count is $1+1+1=3$. Each NADH carries two electrons, and the succinate dehydrogenase route supplies another pair, so one turn exports $3\times 2+2=8$ electrons. This arithmetic is an accounting identity, not an ATP yield calculation. Converting it to ATP requires the separate energy coupling and transport assumptions discussed under oxidative phosphorylation.

For a chosen ideal conversion of $5\mu \mathrm{mol}$ of acetyl groups, multiplication gives $15\mu \mathrm{mol}$ of NADH, $5\mu \mathrm{mol}$ of ubiquinol, $5\mu \mathrm{mol}$ of GTP and $10\mu \mathrm{mol}$ of carbon dioxide. The electron output is $40\mu \mathrm{mol}$. If all these electrons subsequently reach oxygen with no competing sinks, four electrons per oxygen molecule require $10\mu \mathrm{mol}$ of oxygen. That is consumption by the connected electron transport chain; it is not an oxygen term in the cycle's own substrate ledger.

No cycle step directly consumes molecular oxygen. In ordinary aerobic mitochondrial operation, however, the mitochondrial respiratory chain must reoxidize NADH and ubiquinol to restore the oxidized electron carriers. Without that outlet, a finite oxidized-carrier pool cannot sustain continued turnover. Other electron acceptors and other forms of metabolism require their own analysis.^[ref]

The pyruvate dehydrogenase complex acts upstream: one three-carbon pyruvate gives one two-carbon acetyl group, one carbon dioxide and one NADH. These are additional to the cycle ledger.^[ref] Consequently, processing one pyruvate through both stages gives three carbon dioxide and four NADH, while the succinate dehydrogenase contribution and the substrate-level phosphorylation contribution each remain one. Counting the upstream step inside the cycle would obscure where the extra carbon dioxide and NADH arise.

cancer largely reuses normal cellular machinery, but its organization and evolutionary behaviour are not adequately described as one homeostatic control simply being turned up or down. Growth, survival, metabolism, plasticity and tissue remodelling all have normal functions. Malignancy arises when their coordination with the needs of the organism is lost, and selection can then generate new combinations, altered molecular activities and pathological ecological interactions.

Normal proliferation depends on extracellular signals and internal cell-cycle controls. Constitutive receptor or Ras signalling, increased cyclin activity or weakened RB–E2F restraint can make a biological cell divide under conditions in which its neighbours would arrest. These changes exploit existing DNA replication and mitotic machinery rather than inventing a new way to duplicate a genome. Equally, normal apoptosis removes damaged or inappropriate biological cells; a tumour can survive by suppressing this response. Loss of p53 can compromise a network linking stress to arrest, repair, death and other restraints. Mice lacking p53 develop spontaneous tumours despite largely normal development, directly demonstrating the importance of an existing protective programme.^[ref] This does not mean that every cancer must eliminate every p53 output or that all p53 mutations have the same effect.

Many other properties have similarly recognizable antecedents. glycolysis, nutrient uptake and autophagy support normal growth and stress adaptation; their deployment can help cancer biological cells tolerate fluctuating resources. Angiogenic signals normally support development and repair, but sustained production can recruit vessels into a growing tumour. Motility, matrix remodelling and reversible changes in adhesion participate in development and wound repair. cancer can recruit them for invasion, with surrounding fibroblasts and immune biological cells contributing signals and physical routes. Collective breast-cancer invasion, for example, can depend on a conserved basal epithelial programme rather than a completely new locomotor apparatus.^[ref] Immune suppression also uses normal regulatory pathways, although suppressing antitumour immunity conflicts with organismal protection.

The homeostatic interpretation is most useful when it emphasizes constraints and feedback. Normal tissue renewal couples production to biological cell loss and spatial organization. A mutation increasing division, reducing death or changing competitive interactions can unbalance this system even without maximal activation of every pathway. Selection acts on net clonal success, not only on instantaneous proliferation. A slowly cycling population that survives therapy or colonizes a new site may be favoured under particular conditions. Conversely, an excessively strong oncogenic signal can trigger senescence or apoptosis, so successful cancers often combine activating changes with escape from compensating restraints. Different combinations can converge on similar phenotypes.

However, “nothing new” becomes misleading at the molecular level. Some alterations generate a qualitatively changed activity. Cancer-associated IDH1 mutants acquire the ability to reduce alpha-ketoglutarate to R-2-hydroxyglutarate, rather than simply increasing the enzyme's ordinary reaction. metabolite profiling and biochemical assays established this altered catalytic activity.^[ref] gene fusions can join recognition and signalling domains in new regulatory arrangements, while new enhancer contacts or altered splicing can change which molecular combinations are expressed. These innovations still obey familiar chemistry and use inherited components, but that is true of biological innovation generally; it does not make them equivalent to a reversible normal homeostatic response.

cancer is also an evolving population within a changing environment. Genetic and epigenetic variation permit selection for survival during hypoxia, immune attack or treatment. The selected phenotype can depend on the surrounding stroma and on interactions among tumour subclones. Normal wound-healing responses may stop when repair is complete, whereas a tumour can maintain the signals or continually regenerate the damage that recruits them. Altered metabolism, inflammation and genomic instability can create feedback that changes the environment itself. This is not a single biological cell merely ignoring one stop signal, and one successful clone need not benefit either neighbouring cancer biological cells or the host.

Experimentally, the distinction matters. If an existing normal programme is misregulated, correcting the upstream input or restoring feedback may normalize behaviour, but normal tissues using the same programme may also be affected. If an altered protein has a tumour-specific pocket or catalytic dependence, that difference may provide selectivity. Genotype-matched perturbations, measurements of the normal counterpart and tests in tissue context discriminate these cases. A list of cancer-associated phenotypes alone does not determine whether the causal change is quantitative, qualitative or ecological. cancer usually repurposes normal processes, but malignancy emerges from altered control, molecular changes and selection among biological cells; “simply deregulation” understates that causal complexity.

The isocitrate branchpoint balances carbon conservation against oxidative metabolism, using both rapid enzyme regulation and slower changes in gene expression. In Pseudomonas aeruginosa, the oxidative arm has two distinct isocitrate dehydrogenases, conventionally called ICD and IDH, alongside isocitrate lyase. Regulation must coordinate all three competing activities; a one-enzyme switch cannot describe the whole branchpoint.

The carbon logic comes first. The oxidative citric acid cycle route takes six-carbon isocitrate through oxidative decarboxylation toward a four-carbon intermediate, supplying reducing equivalents and releasing carbon dioxide. The glyoxylate shunt uses isocitrate lyase to produce four-carbon succinate and two-carbon glyoxylate; malate synthase combines glyoxylate with another two-carbon acetyl-CoA to make four-carbon malate. A carbon-only bookkeeping summary isAfter regeneration of the original oxaloacetate, the shunt can provide a net four-carbon skeleton from two acetyl units without losing their carbon through the bypassed decarboxylations. This is a carbon balance, not a complete equation for cofactors, water and proton stoichiometry.

Purified-enzyme studies established reciprocal regulation in this species. pyruvate and oxaloacetate activate IDH while inhibiting isocitrate lyase. ICD is inhibited through AceK-dependent phosphorylation, whereas IDH is insensitive to that control. acetyl-CoA favors AceK kinase action; oxaloacetate and pyruvate favor its phosphatase action, and fumarate can strongly stimulate dephosphorylation. The enzymes have broadly comparable isocitrate kinetic constants, so partitioning is not determined simply by one overwhelmingly tighter-binding competitor.^[ref] Thus precursor abundance favors the oxidative route, while precursor shortage and acetyl-unit availability favor conservation through the shunt. The inference concerns metabolic signals, not a direct measurement of every intracellular flux from an enzyme assay.

Why is that feedback appropriate? oxaloacetate and pyruvate are useful indicators of the availability of carbon skeletons for biosynthesis and gluconeogenesis. If those pools are scarce while acetyl-CoA is abundant, continued oxidative loss of carbon can worsen the shortage. Favoring isocitrate lyase conserves substrate for replenishment. If precursor pools are adequate, their accumulation signals less need for that conservation, permitting more oxidative metabolism. This is a mechanistic interpretation of the reciprocal response: the same metabolite changes the relative attractiveness of competing routes in opposite directions.

Covalent and allosteric regulation solve related problems. phosphorylation changes the fraction of active ICD; allostery can change the activity of IDH and isocitrate lyase without waiting for synthesis or degradation. Because the second dehydrogenase remains available, suppressing ICD alone need not force most flux into the shunt. Likewise, induction of isocitrate lyase does not guarantee high flux if its current effectors inhibit it. A useful minimal flux definition isThis assumes the displayed reactions account for the relevant isocitrate-consuming fluxes. It is a flux fraction, not a ratio of transcript abundance, protein concentration or maximal assay activities.

For example, illustrative fluxes $v_{\mathrm{ICL}}=2$, $v_{\mathrm{ICD}}=3$ and $v_{\mathrm{IDH}}=5$ give $f_{\mathrm{shunt}}=0.20$. Inactivating four fifths of ICD while holding the other two rates fixed gives $2/(2+0.6+5)\simeq 0.263$, far from complete redirection. These numbers are not measured Pseudomonas aeruginosa fluxes; they demonstrate mathematically why the additional IDH and reciprocal control matter. In a real cell, isocitrate and effectors would also change, so fixed-rate reasoning is only a diagnostic toy calculation.

Transcription changes the available capacities over longer times. The genes aceA and glcB encode isocitrate lyase and malate synthase. Promoter reporters, DNA-affinity capture and genetic perturbation implicated RccR in carbon-source-dependent repression of the shunt machinery.^[ref] A later study directly identified KDPG as an RccR ligand and linked RccR-dependent control of central carbon genes to aminoglycoside tolerance.^[ref] A metabolite-sensing transcription factor can therefore adjust enzyme supply according to carbon metabolism, while the already present enzymes remain subject to rapid regulation. Reporter expression must be normalized to biomass and growth state; increased luminescence does not directly measure flux.

The branchpoint is important during growth on acetate ion or fatty acids, which supply acetyl units without automatically replacing the four-carbon precursors withdrawn for biomass. The shunt enables net assimilation into gluconeogenic material. However, carbon conservation has a cost: bypassing oxidative steps changes the yield and distribution of reducing equivalents and metabolites such as alpha-ketoglutarate. An exclusive shunt would not meet every requirement of the cell. Flexible partitioning allows the bacterium to exploit changing nutrient mixtures and maintain biosynthetic and energetic demands together.

This flexibility can also influence infection-associated physiology. Changes in oxidative metabolism can alter respiration, proton-motive force and the physiological response to some antibiotics. A survival phenotype is not equivalent to a higher resistance-conferring target-mutation frequency, and an enzyme essential in one carbon source need not be essential in every infection niche. Compare carbon-defined cultures, measure growth and respiration, and test whether the same metabolic perturbation changes both flux and antibiotic killing. The RccR evidence supports a connection to tolerance in the tested conditions rather than a universal therapeutic prediction.

A rigorous test combines carbon-13 metabolic flux analysis, intracellular metabolite measurements, enzyme phosphorylation state and gene-expression measurements. Use individual and combined dehydrogenase perturbations, isocitrate-lyase controls and genetic rescue. Confirm that the flux model can distinguish the oxidative route from the shunt and account for other anaplerotic reactions. The branchpoint is a regulated allocation decision: allostery, ICD phosphorylation and metabolite-responsive transcription cooperate to conserve carbon when precursors are limiting and support oxidative metabolism when their supply permits it.